Introduction
Depression is among the most prevalent and disabling conditions managed in Australian health care, with affective disorders affecting approximately 7.5 per cent of Australians aged 16-85 in any 12-month period (Australian Bureau of Statistics [ABS], 2023). Two treatment modalities dominate clinical responses to it: cognitive behavioural therapy (CBT), a structured psychological intervention targeting the maladaptive cognitions and behaviours that maintain low mood, and pharmacotherapy, most commonly the selective serotonin reuptake inhibitors (SSRIs). Which of the two should be offered first is not an abstract question. It shapes Medicare policy, general practitioner (GP) referral behaviour, Pharmaceutical Benefits Scheme (PBS) expenditure and the daily experience of hundreds of thousands of Australian patients. This essay compares the efficacy evidence for CBT and SSRIs across three dimensions: acute response, relapse prevention and the moderating role of baseline severity. It then considers combination therapy, before examining how access and adherence operate within the Australian system, including the Better Access initiative, GP Mental Health Treatment Plans and national antidepressant prescribing patterns. The essay defends a deliberately nuanced position. CBT warrants default first-line status for mild to moderate depression because its benefits persist after treatment ends; pharmacotherapy remains indispensable at the severe end of the spectrum, ordinarily alongside psychological care; and in present-day Australia it is service structures, rather than the comparative evidence, that too often determine which treatment a patient actually receives.
Acute Efficacy: A Qualified Equivalence
The strongest evidence for SSRI efficacy in the acute phase comes from Cipriani et al. (2018), a network meta-analysis of 522 randomised controlled trials involving 116,477 participants, which found that all 21 antidepressants examined outperformed placebo in adults with major depressive disorder. That finding is frequently cited as settling the question of whether antidepressants work, yet read closely it is more equivocal. The average advantage over placebo was modest, corresponding to a standardised mean difference of approximately 0.30, which translates to roughly one additional responder for every eight to ten patients treated. Effects were larger in more severe samples and varied between agents, with escitalopram and sertraline performing comparatively well on the joint criteria of efficacy and acceptability.
The CBT evidence base is at least as extensive. Cuijpers et al. (2023), synthesising 409 trials with more than 52,000 patients, reported a large pooled effect of CBT over control conditions (g = 0.79). The effect shrank when analyses were restricted to trials at low risk of bias and to care-as-usual comparators, but it remained significant and clinically meaningful. More importantly for the present question, direct comparisons show no meaningful acute difference between the modalities: in a comprehensive network meta-analysis of treatments for adult depression, psychotherapies and pharmacotherapies were statistically indistinguishable at treatment end (Cuijpers et al., 2020).
Both literatures carry inflationary biases, and they run in opposite directions. Antidepressant trials are vulnerable to publication bias and to functional unblinding when side effects reveal group allocation, while psychotherapy trials cannot blind participants at all and are prone to researcher allegiance effects. Because these distortions are roughly symmetrical, the most defensible conclusion is a qualified equivalence: for the average acute episode, neither treatment can claim clear superiority on response or remission.
Beyond the Acute Phase: Relapse and Durability
The comparison changes decisively once treatment ends. Antidepressants appear to suppress symptoms while they are taken rather than modify the underlying vulnerability, so their protective effect is largely conditional on continued use. CBT, by contrast, shows an enduring effect that outlasts the final session. In the landmark continuation study by Hollon et al. (2005), patients who had responded to cognitive therapy and then had all treatment withdrawn relapsed at a rate of 31 per cent over the following year, compared with 76 per cent among medication responders withdrawn to placebo and 47 per cent among patients who continued taking their medication. Prior cognitive therapy, in other words, protected patients after it ended more effectively than ongoing pharmacotherapy protected patients still receiving it.
This durability differential replicates at meta-analytic scale. The advantage of CBT over pharmacotherapy emerges most clearly at 6-12 month follow-up, when acute equivalence gives way to superiority for the psychological treatment (Cuijpers et al., 2023). Sequential designs reinforce the point. Guidi and Fava (2021) found that psychotherapy delivered after acute-phase pharmacotherapy significantly reduced relapse and recurrence, with particular value where psychological treatment supported the tapering of antidepressants.
For a condition as recurrent as depression, durability is not a secondary outcome. Much of depression’s lifetime burden accrues through repeated episodes, and a treatment that substantially lowers post-treatment relapse alters the long-run illness trajectory in a way that acute response rates cannot capture. On this criterion the evidence favours CBT, and the conventional framing of the two treatments as equals understates the difference between them.
Does Severity Settle the Question?
A common compromise assigns CBT to milder cases and medication to severe ones. The evidence supports only half of that formula. Fournier et al. (2010), pooling patient-level data from placebo-controlled trials, found that the advantage of antidepressants over placebo was minimal to non-existent at mild and moderate symptom levels and became substantial only in very severe depression. The pattern is salient for Australia, where around nine in ten mental health related prescriptions are written in general practice (Australian Institute of Health and Welfare [AIHW], 2024), frequently for presentations at the milder end of the spectrum where the drug-placebo margin is thinnest.
The inverse claim, that CBT loses potency as severity rises, finds little support. Weitz et al. (2015), in an individual patient data meta-analysis of sixteen trials directly comparing CBT with antidepressant medication, found that baseline severity did not moderate the relative effectiveness of the two treatments. A small overall advantage for medication on clinician-rated symptoms (d = 0.16) was constant across the severity range, and on no outcome did medication pull further ahead among the most severely depressed patients. Severity is therefore a poor criterion for choosing between the monotherapies. What severity does justify is intensification. Severe, melancholic or psychotic presentations warrant prompt pharmacotherapy, usually combined with psychological treatment, a position reflected in the Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders (Malhi et al., 2021).
Combination and Sequencing
Framing CBT and SSRIs as rivals also obscures their demonstrated complementarity. Combined treatment outperforms both psychotherapy alone and pharmacotherapy alone by a standardised mean difference of approximately 0.30, an increment comparable to the entire advantage of antidepressants over placebo (Cuijpers et al., 2020). The gain appears most valuable where severity, chronicity or comorbidity raises the cost of initial non-response. Sequencing evidence extends the logic across the illness course: psychological therapy introduced during the continuation phase, or while medication is withdrawn, consolidates remission and reduces recurrence (Guidi & Fava, 2021). Australian guidance is consistent with this hierarchy, positioning psychological interventions as foundational at every level of severity and adding antidepressants for moderate to severe episodes rather than substituting them for psychological care (Malhi et al., 2021). The clinically meaningful question is therefore not which treatment wins outright, but which should ordinarily come first, which should be added, for whom, and when.
Access and Adherence in the Australian System
Efficacy hierarchies mean little if the system cannot deliver the preferred treatment. In Australia the two modalities are reached through markedly different funnels. Subsidised psychological therapy runs through the Better Access initiative: a GP prepares a Mental Health Treatment Plan and refers the patient for Medicare-rebated care, capped at ten individual sessions per calendar year, with a review required after the first six sessions before the remainder are released. The temporary pandemic expansion to twenty sessions ended in December 2022. Pharmacotherapy, by contrast, requires only a standard consultation and a PBS prescription that costs a general patient no more than about A$32 for a month’s supply, and concessional patients considerably less.
The consequences are visible in national data. More than four million Australians were dispensed a mental health related medication in 2022-23, the large majority antidepressants (AIHW, 2024), and Australia has for years recorded one of the highest antidepressant dispensing rates in the OECD (Davey & Chanen, 2016). The national evaluation of Better Access found that users who completed a course of therapy generally improved, but the median user attended only four to five sessions, well below the 12-16 session dose delivered in the trials that underpin CBT’s evidence base, and out-of-pocket gap fees, averaging around A$90 per session and rising, fell hardest on low-income and regional patients (Pirkis et al., 2022). Because the psychology workforce is concentrated in metropolitan areas, the subsidy is most usable precisely where alternatives are most plentiful.
Adherence problems cut in both directions. A substantial proportion of patients cease antidepressants within the first months of treatment, often without medical review (Malhi et al., 2021), while roughly one quarter of CBT patients drop out before completing therapy (Fernandez et al., 2015). Neither pathway reliably delivers an adequate dose of its own treatment. One partial corrective is distinctly Australian. Federally funded digital services such as MindSpot and This Way Up provide clinician-guided CBT programs at no cost to the patient, and meta-analytic evidence indicates that guided internet CBT achieves outcomes comparable to face-to-face delivery for mild to moderate depression (Andrews et al., 2018). Digital delivery is no answer to severe illness, but it directly attacks the cost, distance and workforce barriers that currently push Australian patients towards the prescription pad.
The Case for Medication First: Counterargument and Rebuttal
The strongest counterargument holds that pharmacotherapy should remain first-line on pragmatic grounds. If acute efficacy is equivalent, an SSRI can be started today by any GP in the country at PBS prices, with no waiting list, no gap fees and no weekly attendance, and general practice reaches rural and low-income communities that the psychology workforce demonstrably does not. On this view, recommending CBT first is a counsel of perfection: it trades a treatment patients can obtain immediately for one that many cannot obtain at all, and untreated weeks carry their own harms.
The pragmatic case deserves partial acceptance, but it fails as a general rule for three reasons. First, it prices durability at zero. Acute equivalence conceals a large post-treatment difference in relapse (Hollon et al., 2005), so the convenient choice today purchases repeat episodes, repeat consultations and open-ended maintenance prescribing tomorrow. Second, the accessibility advantage is narrower than it appears, because real-world persistence with antidepressants is poor (Malhi et al., 2021); a treatment quickly abandoned is not meaningfully more accessible than one that is harder to begin. Third, the scalability objection is weakening as guided digital CBT provides immediate, free, evidence-based access without geographic limits (Andrews et al., 2018). What survives of the counterargument still matters. For severe, melancholic or high-risk presentations, and for patients with an informed preference for medication, prompt prescribing is defensible and frequently essential (Fournier et al., 2010; Malhi et al., 2021). The rebuttal is aimed at medication-first as a default for the mild to moderate majority, not at medication itself.
Conclusion
The comparative evidence crowns no single winner, but it does not license indifference. CBT and SSRIs are approximately equivalent in the acute phase; CBT’s benefits endure after treatment ends while antidepressants protect chiefly while taken; severity justifies adding medication rather than withholding psychological therapy; and combination outperforms either monotherapy where illness is severe or persistent. The defensible first-line position is therefore stratified: CBT, including guided digital delivery, as the default for mild to moderate depression; early pharmacotherapy, ordinarily alongside psychological treatment, for severe presentations; and informed patient preference respected throughout. Australia’s difficulty is that its service architecture inverts this ordering. Ten capped sessions with rising gap fees compete against an uncapped, near-universal PBS subsidy, and national prescribing patterns suggest that the system’s path of least resistance, not the comparative evidence, is deciding treatment for a large share of patients. Aligning first-line practice with the evidence is consequently less a clinical problem than a policy one, and reform of session caps, workforce distribution and digital integration will determine whether the answer produced in trials becomes the answer delivered in Australian consulting rooms.
References
Andrews, G., Basu, A., Cuijpers, P., Craske, M. G., McEvoy, P., English, C. L., & Newby, J. M. (2018). Computer therapy for the anxiety and depressive disorders is effective, acceptable and practical health care: An updated meta-analysis. Journal of Anxiety Disorders, 55, 70-78.
Australian Bureau of Statistics. (2023). National Study of Mental Health and Wellbeing, 2020-2022.
Australian Institute of Health and Welfare. (2024). Mental health services in Australia.
Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., Leucht, S., Ruhe, H. G., Turner, E. H., Higgins, J. P. T., Egger, M., Takeshima, N., Hayasaka, Y., Imai, H., Shinohara, K., Tajika, A., Ioannidis, J. P. A., & Geddes, J. R. (2018). Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: A systematic review and network meta-analysis. The Lancet, 391(10128), 1357-1366.
Cuijpers, P., Miguel, C., Harrer, M., Plessen, C. Y., Ciharova, M., Ebert, D., & Karyotaki, E. (2023). Cognitive behavior therapy vs. control conditions, other psychotherapies, pharmacotherapies and combined treatment for depression: A comprehensive meta-analysis including 409 trials with 52,702 patients. World Psychiatry, 22(1), 105-115.
Cuijpers, P., Noma, H., Karyotaki, E., Vinkers, C. H., Cipriani, A., & Furukawa, T. A. (2020). A network meta-analysis of the effects of psychotherapies, pharmacotherapies and their combination in the treatment of adult depression. World Psychiatry, 19(1), 92-107.
Davey, C. G., & Chanen, A. M. (2016). The unfulfilled promise of the antidepressant medications. Medical Journal of Australia, 204(9), 348-350.
Fernandez, E., Salem, D., Swift, J. K., & Ramtahal, N. (2015). Meta-analysis of dropout from cognitive behavioral therapy: Magnitude, timing, and moderators. Journal of Consulting and Clinical Psychology, 83(6), 1108-1122.
Fournier, J. C., DeRubeis, R. J., Hollon, S. D., Dimidjian, S., Amsterdam, J. D., Shelton, R. C., & Fawcett, J. (2010). Antidepressant drug effects and depression severity: A patient-level meta-analysis. JAMA, 303(1), 47-53.
Guidi, J., & Fava, G. A. (2021). Sequential combination of pharmacotherapy and psychotherapy in major depressive disorder: A systematic review and meta-analysis. JAMA Psychiatry, 78(3), 261-269.
Hollon, S. D., DeRubeis, R. J., Shelton, R. C., Amsterdam, J. D., Salomon, R. M., O’Reardon, J. P., Lovett, M. L., Young, P. R., Haman, K. L., Freeman, B. B., & Gallop, R. (2005). Prevention of relapse following cognitive therapy vs medications in moderate to severe depression. Archives of General Psychiatry, 62(4), 417-422.
Malhi, G. S., Bell, E., Bassett, D., Boyce, P., Bryant, R., Hazell, P., Hopwood, M., Lyndon, B., Mulder, R., Porter, R., Singh, A. B., & Murray, G. (2021). The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Australian and New Zealand Journal of Psychiatry, 55(1), 7-117.
Pirkis, J., Currier, D., Harris, M., & Mihalopoulos, C. (2022). Evaluation of the Better Access initiative: Final report. University of Melbourne.
Weitz, E. S., Hollon, S. D., Twisk, J., van Straten, A., Huibers, M. J. H., David, D., DeRubeis, R. J., Dimidjian, S., Dunlop, B. W., Cristea, I. A., Faramarzi, M., Hegerl, U., Jarrett, R. B., Kheirkhah, F., Kennedy, S. H., Mergl, R., Miranda, J., Mohr, D. C., Rush, A. J., … Cuijpers, P. (2015). Baseline depression severity as moderator of depression outcomes between cognitive behavioral therapy vs pharmacotherapy: An individual patient data meta-analysis. JAMA Psychiatry, 72(11), 1102-1109.